399 results in Exploration of Targeted Anti-tumor Therapy
Latest
Sort by :
- Latest
- Most Viewed
- Most Downloaded
- Most Cited
Open Access
Review
Gastrointestinal disorders as immune-related adverse events
Daniele Balducci ... Luca Maroni
Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:174–186
This article belongs to the special issue Immunotherapy in Cancer Patients
Open Access
Review
Liquid biopsy in NSCLC: a new challenge in radiation therapy
Annarita Perillo ... Ida Rosalia Scognamiglio
Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:156–173
This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
Open Access
Review
Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
Paolo Tarantino ... Giuseppe Curigliano
Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:139–155
Open Access
Review
Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review
Valeria Cognigni ... Rossana Berardi
Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:122–138
This article belongs to the special issue Immunotherapy in Cancer Patients
Open Access
Review
Aptamers and antibodies: rivals or allies in cancer targeted therapy?
Lisa Agnello ... Laura Cerchia
Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:107–121
Open Access
Review
Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
Sara Ovejero, Jerome Moreaux
Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:65–106
This article belongs to the special issue Off-Label Drugs and -Omics Data in Cancer Treatment
Open Access
Review
Immunotherapy in gynecological cancers
Domenica Lorusso ... Giovanni Scambia
Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:48–64
This article belongs to the special issue Immunotherapy in Cancer Patients
Open Access
Review
Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy
Viviana De Rosa ... Francesca Iommelli
Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:36–47
This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
Open Access
Review
Emerging role of pioneer transcription factors in targeted ERα positive breast cancer
Honey Pavithran, Ranjith Kumavath
Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:26–35
This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
Open Access
Review
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
Luca Cantini ... Rossana Berardi
Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:1–25
This article belongs to the special issue Immunotherapy in Cancer Patients
Open Access
Review
An overview of immune checkpoint inhibitors in breast cancer
Federica Miglietta ... Nicla La Verde
Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:452–472
This article belongs to the special issue Immunotherapy in Cancer Patients
Open Access
Review
Circulating biomarkers in malignant pleural mesothelioma
Giuseppe Viscardi ... Giulia Galli
Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:434–451
This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
Open Access
Letter to the Editor
Is hyperprogressive disease a specific phenomenom of immunotherapy?
Marta Brambilla ... Mario Occhipinti
Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:427–433
This article belongs to the special issue Immunotherapy in Cancer Patients
Open Access
Review
An overview of the potential anticancer properties of cardamonin
Shanaya Ramchandani ... Manoj Garg
Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:413–426
This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
Open Access
Review
Targeting transcription factors in cancer drug discovery
Partha Mitra
Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:401–412
This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
Open Access
Review
Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
Marialucia Iacovino ... Francesca Sparano
Published: December 28, 2020 Explor Target Antitumor Ther. 2020;1:391–400
This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
Open Access
Review
Novel approaches for the rational design of PROTAC linkers
Almaz Zagidullin ... Emil Bulatov
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
Open Access
Review
Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer
Sosmitha Girisa ... Ajaikumar B. Kunnumakkara
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:313–342
This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
Open Access
Case Report
Pseudoprogression in lung cancer: a case report
Giulia Meoni ... Angela Stefania Ribecco
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:372–380
This article belongs to the special issue Immunotherapy in Cancer Patients
Open Access
Original Article
Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer
Milene Volpato ... Valerie Speirs
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:355–371
Previous